0001564590-21-000879.txt : 20210111 0001564590-21-000879.hdr.sgml : 20210111 20210111171018 ACCESSION NUMBER: 0001564590-21-000879 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210111 DATE AS OF CHANGE: 20210111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 21521542 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 kzr-8k_20210108.htm FORM 8-K kzr-8k_20210108.htm
false 0001645666 0001645666 2021-01-08 2021-01-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 8, 2021

 

 

KEZAR LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-38542

47-3366145

(state or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

 

 

4000 Shoreline Court, Suite 300

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

 

Registrant's telephone number, including area code:  (650) 822-5600

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

KZR

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

Kezar Life Sciences, Inc. (the “Company”) preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2020 was approximately $140.4 million and that it had 46.4 million shares of common stock outstanding as of December 31, 2020. These preliminary estimates are not a comprehensive statement of the Company’s financial results for the year ended December 31, 2020 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. The Company’s actual consolidated cash, cash equivalents and marketable securities balance and shares of common stock outstanding as of December 31, 2020 may differ from these estimates due to the completion of the Company’s year-end closing and auditing procedures.

The information provided in this Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2021, the Compensation Committee (the “Committee”) of the Board of Directors of the Company approved the following compensation decisions and annual equity awards for the Company’s named executive officers (each, an “Executive”).  

The Committee approved 2020 cash bonuses, 2021 annual base salaries, 2021 bonus targets and option grants to purchase shares of the Company’s common stock (each, an “Option”) for the Executives, in the amounts set forth in the table below:

Name and Title

2020 Cash

Bonus

2021 Annual

Base Salary

2021 Bonus

Target

Option Grant (Shares)

John Fowler

Chief Executive Officer and Director

$243,789

$567,000

50%

1,200,000

Christopher Kirk, Ph.D.

President, Chief Scientific Officer and Director

$152,167

$443,000

40%

260,000

Marc Belsky

Chief Financial Officer and Secretary

$142,646

$405,000

40%

220,000

The 2021 annual base salaries are effective as of January 1, 2021.  Each Option was granted pursuant to the Company’s 2018 Equity Incentive Plan and has (i) a vesting commencement date of January 1, 2021, (ii) an exercise price of $5.45 per share, the closing price of the Company’s common stock on January 8, 2021, and (iii) a term of ten years following the grant date.  Each Option will vest in 48 equal monthly installments over four years following the vesting commencement date, subject to the Executive’s continued service with the Company on each applicable vesting date.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KEZAR LIFE SCIENCES, INC.

 

 

 

 

 

By:

 

/s/ Marc L. Belsky

 

 

 

Marc L. Belsky

 

 

 

Chief Financial Officer and Secretary

 

Dated:  January 11, 2021

 

 EX-101.SCH 2 kzr-20210108.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 kzr-20210108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 kzr-20210108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 kzr-8k_20210108_htm.xml IDEA: XBRL DOCUMENT 0001645666 2021-01-08 2021-01-08 false 0001645666 8-K 2021-01-08 KEZAR LIFE SCIENCES, INC. DE 001-38542 47-3366145 4000 Shoreline Court Suite 300 South San Francisco CA 94080 650 822-5600 false false false false Common Stock, $0.001 par value KZR NASDAQ true true XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Jan. 08, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 08, 2021
Entity Registrant Name KEZAR LIFE SCIENCES, INC.
Entity Central Index Key 0001645666
Entity Incorporation State Country Code DE
Entity File Number 001-38542
Entity Tax Identification Number 47-3366145
Entity Address, Address Line One 4000 Shoreline Court
Entity Address, Address Line Two Suite 300
Entity Address City Or Town South San Francisco
Entity Address State Or Province CA
Entity Address Postal Zip Code 94080
City Area Code 650
Local Phone Number 822-5600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol KZR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports kzr-8k_20210108.htm kzr-20210108.xsd kzr-20210108_lab.xml kzr-20210108_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kzr-8k_20210108.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "kzr-8k_20210108.htm" ] }, "labelLink": { "local": [ "kzr-20210108_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "kzr-20210108_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "kzr-20210108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kzr", "nsuri": "http://kezarlifesciences.com/20210108", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kzr-8k_20210108.htm", "contextRef": "C_0001645666_20210108_20210108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kzr-8k_20210108.htm", "contextRef": "C_0001645666_20210108_20210108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://kezarlifesciences.com/20210108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001564590-21-000879-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-000879-xbrl.zip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end